|
Mar 14
|
Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks
|
|
Mar 13
|
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
|
|
Mar 12
|
Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT)
|
|
Mar 11
|
Billionaire Ray Dalio and Insiders Love These 10 Stocks
|
|
Mar 7
|
Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT)
|
|
Mar 4
|
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
|
|
Mar 4
|
Sarepta Therapeutics to Present at Upcoming Investor Conferences
|
|
Feb 23
|
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
|
|
Feb 21
|
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
|
|
Feb 21
|
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
|
|
Feb 20
|
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
|
|
Jan 16
|
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
|
|
Jan 16
|
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
|
|
Jan 15
|
Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why
|
|
Jan 12
|
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
|
|
Jan 11
|
Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study
|
|
Jan 11
|
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
|
|
Jan 11
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
Jan 11
|
The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics
|
|
Jan 10
|
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
|